Table 1.
Demographics, treatment, thymic epithelial tumor subtypes, staging, and outcome of the study population (n = 81).
| Carcinoma a | Thymoma a | |||
|---|---|---|---|---|
| A | B3 | MNTLS | ||
| Number of patients | 37 | 25 | 11 | 8 |
| Male, n (%) | 20 (54.1) | 11 (44.0) | 4 (36.4) | 2 (25.0) |
| Age in years, median (Q1, Q3) | 56.3 | 66.4 | 53.4 | 74.4 |
| (48.0, 69.9) | (59.4, 75.3) | (41.4, 65.6) | (65.7, 78.9) | |
| Resection, n (%) | ||||
| Complete | 24 (68.6) | 25 (100.0) | 9 (100.0) | 8 (100.0) |
| Incomplete | 7 (20.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Biopsy | 4 (11.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Thymic carcinoma subtypes, n (%) | ||||
| Squamous cell carcinoma | 24 (64.9) | |||
| Adenocarcinoma | 3 (8.1) | |||
| Small cell carcinoma | 2 (5.4) | |||
| Undifferentiated carcinoma | 2 (5.4) | |||
| Mucoepidermoid carcinoma | 2 (5.4) | |||
| Lymphoepithelial carcinoma | 2 (5.4) | |||
| Sarcomatoid carcinoma | 1 (2.7) | |||
| Adenosquamous carcinoma | 1 (2.7) | |||
| Tumor size (if completely resected and primary tumor) in cm, median (Q1, Q3) | 5.5 (4.2, 7.5) | 5 (3.3, 7.8) | 5 (4.2, 7.5) | 3.9 (3.0, 4.7) |
| T-stage, n (%) | ||||
| 1a/b | 17 (51.5) | 23 (92.0) | 7 (77.8) | 7 (87.5) |
| 3 | 16 (48.5) | 2 (8.0) | 2 (22.2) | 1 (12.5) |
| N-stage, n (%) | ||||
| 0 | 10 (52.6) | 15 (100.0) | 7 (100.0) | 4 (100.0) |
| 1 | 8 (42.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| 2 | 1 (5.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| M-stage, n (%) | ||||
| 0 | 27 (79.4) | 25 (100.0) | 8 (88.9) | 8 (100.0) |
| 1a | 3 (8.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| 1b | 4 (11.8) | 0 (0.0) | 1 (11.1) | 0 (0.0) |
| TNM stage, n (%) | ||||
| I | 5 (27.8) | 15 (100.0) | 6 (75.0) | 3 (75.0) |
| IIIA | 3 (16.7) | 0 (0.0) | 1 (12.5) | 1 (25.0) |
| IVA | 7 (38.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| IVB | 3 (16.7) | 0 (0.0) | 1 (12.5) | 0 (0.0) |
| Additional Therapies, n (%) | ||||
| No | 7 (21.2) | 23 (92.0) | 8 (88.9) | 8 (100.0) |
| Adj radiation | 7 (21.2) | 1 (4.0) | 0 (0.0) | 0 (0.0) |
| Adj chemo | 1 (3.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Neoadj chemo | 1 (3.0) | 1 (4.0) | 0 (0.0) | 0 (0.0) |
| Neoadj and adj chemo and adj radiation | 2 (6.1) | 0 (0.0) | 1 (11.1) | 0 (0.0) |
| Neoadj and adj radiation | 1 (3.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Neoadj radiation | 2 (6.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Neoadj chemoradiation | 2 (6.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Neoadj and adj radiation and neoadj chemo | 1 (3.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Adj chemoradiation | 7 (21.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Neoadj chemo and adj radiation | 1 (3.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Neoadj and adj chemo and neoadj radiation | 1 (3.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Follow up | ||||
| n | 35 | 25 | 9 | 8 |
| Median months of follow up (range) | 31.5 | 44.2 | 57.6 | 63.2 |
| (2.2-240.3) | (1.4-238.4) | (1.5-114.0) | (0.1-118.4) | |
| Patients with recurrence/metastasis, n | 15 | 0 | 3 | 0 |
| Median months to first recur/met | 41.2 | NA | 68.4 | NA |
| 5-year recur/met-free survival, % (95% CI) b | 39.7 | NA | 64.3 | NA |
| (17.7, 61.7) | NA | (23.0, 100.0) | NA | |
| Alive w/o disease, n | 11 | 21 | 5 | 7 |
| Alive with disease, n | 5 | 0 | 2 | 0 |
| Died of disease, n | 7 | 0 | 0 | 0 |
| Months to death of disease, range | 2.3-54.5 | NA | NA | NA |
| Died of other cause, n | 2 | 2 | 0 | 1 |
| Died of unknown cause, n | 10 | 2 | 2 | 0 |
a Frequencies not adding to the column total indicate missing data. b Estimated with the Kaplan–Meier method; Adj, adjuvant; neoadj, neoadjuvant; chemo, chemotherapy; recur, recurrence; met, metastasis; w/o, without; NA, not applicable.